Plasma tissue inhibitor of metalloproteinases-1 (TIMP-1): A novel biological marker in the detection of primary colorectal cancer. Protocol outlines of the Danish-Australian endoscopy study group on colorectal cancer detection

Scandinavian Journal of Gastroenterology

Volumn 43, Issue 2, 2008, Pages 242-248

  Nielsen, Hans Jørgen ^a,e   Brünner, Nils ^b   Frederiksen, Camilla ^a   Lomholt, Anne Fog ^a   King, Denis ^c   Jørgensen, Lars Nannestad ^d   Olsen, Jesper ^d   Rahr, Hans B ^d   Thygesen, Knud ^d   Hoyer, Ute ^d   Laurberg, Søren ^d   Christensen, Ib Jarle ^a  

^a HVIDOVRE HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c St George Private Hospital   (Australia)

^d Danish Australian Endoscopy Study Group on Colorectal Cancer Detection

^e UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ARTICLE; BLOOD SAMPLING; BLOOD TESTIS BARRIER; BREAST CANCER; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER REGISTRY; CANCER RISK; CANCER SCREENING; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COLONOSCOPY; COLORECTAL CANCER; CROHN DISEASE; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCULT BLOOD; PRACTICE GUIDELINE; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; SIGMOIDOSCOPY; ULCERATIVE COLITIS; ULTRASOUND;

CLINICAL TRIALS AS TOPIC; COLONOSCOPY; COLORECTAL NEOPLASMS; DENMARK; HUMANS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TUMOR MARKERS, BIOLOGICAL; VALIDATION STUDIES AS TOPIC;

EID: 38549119828     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.1080/00365520701523439     Document Type: Article

References (44)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics. CA Cancer J Clin 2002;55:74-108.
2. Ytting H, Jensenius JC, Thiel S, Christensen IJ, Nielsen HJ. Serum MASP-2 in colorectal cancer: relation to recurrence and mortality. Clin Cancer Res 2005;11:1441-6.
3. Srivastava S, Verma M, Henson DE. Biomarkers for early detection of colon cancer. Clin Cancer Res 2001;7:1118-26.
4. Provenzale D, Gray RN. Colorectal cancer screening and treatment: review of outcomes research. J Natl Cancer Inst Monogr 2004;33:45-55.
5. Ransohoff D. Colon cancer screening in 2005: status and challenges. Gastroenterology 2005;128:1685-95.
6. Kronborg O, Fenger C, Olsen J, Jørgensen OD, Søndergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996;348:1467-71.
7. Hardcastle JD, Chamberlain JO, Robinson MH, Moss SM, Amar SS, Balfour TW, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996;348:1472-7.
8. Mapp TJ, Hardcastle JD, Moss SM, Robinson MH. Survival of patients with colorectal cancer diagnosed in a randomised controlled trial of faecal occult blood screening. Br J Surg 1999;86:1286-91.
9. Kronborg O, Jørgensen OD, Fenger C, Rasmussen M. Randomised study of biennial screening with a faecal occult blood test: results after nine screening rounds. Scand J Gastroenterol 2004;39:846-51.
10. Heresbach D, Manfredi S, D'halluin PN, Bretagne JF, Branger B. Review in depth and meta-analysis of controlled trials on colorectal cancer screening by a faecal occult blood test. Eur J Gastroenterol Hepatol 2006;18:427-33.
11. Young GP, St. John JB, Winawer SJ, Rozen P. Choice of fecal occult blood tests for colorectal cancer screening: recommendations based on performance characteristics in population studies. Am J Gastroenterol 2002;97:2499-507.
12. Nadel MR, Shapiro JA, Klabunde CN, Seeff LC, Uhler R, Smith RA, et al. A national survey of primary care physicians' methods for screening for fecal occult blood. Ann Intern Med 2005;142:86-94.
13. Stokamer CL, Tenner CT, Chaudhuri J, Vazquez E, Bini EJ. Randomized controlled trial of the impact of intensive patient education on compliance with fecal occult blood testing. J Gen Intern Med 2005;20:278-82.
14. Ransohoff DF. Rules of evidence for cancer molecular marker discovery and validation. Nature Rev 2004;4:309-14.
15. Quyang DL, Chen JJ, Getzenberg RH. Noninvasive testing for colorectal cancer: a review. Am J Gastroenterol 2005;100:1393-403.
16. Collins JF, Lieberman DA, Durbin TE, Weiss DG. Accuracy of screening for fecal occult blood on a single stool sample obtained by digital rectal examination: a comparison with recommended sampling practice. Ann Intern Med 2005;142:81-5.
17. Holten-Andersen MN, Murphy G, Nielsen HJ, Pedersen AN, Christensen IJ, Hoyer-Hansen G, et al. Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer. Br J Cancer 1999;80:495-503.
18. Wurtz SO, Schrohl AS, Sorensen NM, Lademann U, Christensen IJ, Mouridsen H, et al. Tissue inhibitor of metalloproteinases-1 in breast cancer. Endocr Relat Cancer 2005;12:215-27.
19. Holten-Andersen MN, Christensen IJ, Nielsen HJ, Murphy G, Christensen IJ, Stetler-Stevenson W, et al. Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer. Clin Cancer Res 2002;8:156-64.
20. Waas ET, Hendriks T, Lomme RM, Wobbes T. Plasma levels of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 correlate with disease stage and survival in colorectal cancer patients. Dis Colon Rectum 2005;48:700-10.
21. Hayes DF, Bast RC, Desch CE, Fritsche H Jr, Kemeny NE, Jessup JM, et al. Tumor Marker Utility Grading System: a framework to evaluate clinical utility of tumors markers. J Natl Cancer Inst 1996;88:1456-66.
22. Holten-Andersen MN, Schrohl AS, Brünner N, Nielsen HJ, Högdall CK, Högdall EV. Evaluation of sample handling in relation to levels of tissue inhibitor of metalloproteinases-1 measured in blood by immunoassay. Int J Biol Markers 2003;18:170-6.
23. Holten-Andersen MN, Nielsen HJ, Sørensen S, Jensen V, Brünner N, Christensen IJ. Tissue inhibitor of metalloproteinases-1 in the postoperative monitoring of colorectal cancer. Eur J Cancer 2006;42:1889-96.
24. Maxwell PR, Timms PM, Chandran S, Gordon D. Peripheral blood level alterations of TIMP-1, MMP-2 and MMP-9 in patients with type-1 diabetes. Diabet Med 2001;18:777-80.
25. Lee SW, Song KE, Shin DS, Ahn SM, Ha ES, Kim DJ, et al. Alterations in peripheral blood levels of TIMP-1, MMP-2 and MMP-9 in patients with type-2 diabetes. Diabetes Res Clin Pract 2005;69:175-9.
26. Flisiak R, Maxwell P, Prokopowicz D, Timms PM, Panasiuk A. Plasma tissue inhibitor of metalloproteinases-1 and transforming growth factor beta 1: possible non-invasive biomarkers of hepatic fibrosis in patients with chronic B and C hepatitis. Hepatogastroenterology 2002;49:1369-72.
27. Cavusoglu E, Ruwende C, Chopra V, Yanamadala S, Eng C, Clark LT, et al. Tissue inhibitor of metalloproteinase-s (TIMP-1) is an independent predictor of all-cause mortality, cardiac mortality and myocardial infarction. Am Heart J 2001;151:1101-8.
28. Flisiak I, Porebski P, Chodynicka B. Effect of psoriasis activity on metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in plasma and lesional scales. Acta Derm Venerol 2006;86:17-21.
29. Yoshikawa T, Tsuburaya A, Kobayashi O, Sairenji M, Motohashi H, Yanoma S, et al. Prognostic value of tissue inhibitor of matrix metalloproteinase-1 in plasma of patients with gastric cancer. Cancer Lett 2000;151:81-6.
30. Susskind H, Hymowitz MH, Lau YH, Atkins HL, Hurewitz AN, Lalentine ES, et al. Increased plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinases-1 in lung and breast cancer are altered during chest radiotherapy. Int J Radiat Oncol Biol Phys 2003;56:1161-9.
31. Jensen MK, Holten-Andersen MN, Riisbro R, de Nully Brown P, Larsen MB, Kjeldsen L, et al. Elevated plasma levels of TIMP-1 correlate with plasma suPAR/uPA in patients with chronic myeloproliferative disorders. Eur J Haematol 2003;71:377-84.
32. Neugut AI, Garbowski GC, Waye JD, Forde KA, Treat MR, Tasi JL, et al. Diagnostic yield of colorectal neoplasia with colonoscopy for abdominal pain, change in bowel habits, and rectal bleeding. Am J Gastroenterol 1993;88:1179-83.
33. Bulow S, Christensen IJ. Sigmoidoscopy as primary examination in patients with bowel symptoms. Ugeskr Larger 2001;163:6573-6.
34. Mathew J, Shankar P, Aldean IM. Audit on flexible sigmoidoscopy for rectal bleeding in a district general hospital: are we over-loading the resources? Postgrad Med J 2004;80:38-40.
35. Dove-Irwin I, Sasieni P, Adams J, Thomas HJ. Prevention of colorectal cancer by colonoscopic surveillance in individuals with a family history of colorectal cancer: 16 year, prospective, follow-up study. Br Med J 2005;331:1033-4.
36. Tayabjee MH, Lip GY, Blann AD, Macfadyen RJ. Effects of age, gender, ethnicity, diurnal variation and exercise on circulating levels of matrix metalloproteinases (MMP)-1 and -9, and their inhibitor, tissue inhibitors of matrix metalloproteinses (TIMP)-1 and -2. Thromb Res 2005;115:205-10.
37. Harrell FE, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996;15:361-87.
38. Liebermann DA, Weiss DG. One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon. N Engl J Med 2001;345:555-60.
39. Longacre AV, Cramer LD, Gross CP. Screening colonoscopy use among individuals at higher colorectal cancer risk. J Clin Gastroenterol 2006;40:490-6.
40. Cobb WS, Heniford BT, Sigmon HB, Hasan R, Simms C, Kercher KW, et al. Colonoscopic perforations: incidence, management, and outcomes. Am Surg 2004;70:757-8.
41. Iqbal CW, Chun YS, Farley DR. Colonoscopic perforations: a retrospective review. J Gastrointest Surg 2005;9:1229-35.
42. Levin TR, Palitz A, Grossman S, Conell C, Finkler L, Ackerson L, et al. Predicting advanced proximal colonic neoplasia with screening sigmoidoscopy. JAMA 1999;281:1611-7.
43. Imperiale TF, Wagner DR, Lin CY, Larkin GN, Rogge JD, Ransohoff DF. Using risk for advanced proximal colonic neoplasia to tailor endoscopic screening for colorectal cancer. Ann Intern Med 2003;139:959-65.
44. Burke CA, Elder K, Lopez R. Screening for colorectal cancer with flexible sigmoidoscopy: is a 5-yr interval appropriate? A comparison of the detection of neoplasia 3 yr and 5 yr after a normal examination. Am J Gastroenterol 2006;101:1329-32.